PRESS RELEASE Rokote Laboratories and GlobeVAC Launch Collaboration to Enable Ambient-Temperature Storage of the FINVAC Intranasal Vaccine Platform

by Okapit | Nov 11, 2026 | Latest news, News

Helsinki, Finland, 10.11.2026 Rokote Laboratories Finland Oy and GlobeVAC Oy have entered into a strategic collaboration to evaluate the application of GlobeVAC’s stabilization technology to the FINVAC intranasal vaccine platform. The objective of the...

Rokote Laboratories Finland receives a second clinical trial authorization for FINVAC COVID-19 vaccine

by Okapit | Dec 18, 2025 | Latest news, News

Rokote Laboratories Finland Oy is proud to announce that we have received Clinical Trial Authorization (CTA) for our second Phase I clinical trial of the intranasal COVID-19 vaccine. The upcoming study, titled:”A Phase 1a, single-blind, randomized comparative...

Terhi Reunama Appointed as Head of Clinical Trial Operations

by Okapit | Nov 26, 2025 | Latest news, News

We are pleased to announce the appointment of Terhi Reunama as our new Head of Clinical Trial Operations. Terhi brings nearly 30 years of clinical research experience from both the pharmaceutical industry and CRO organizations. A registered nurse with a Bachelor of...

Our Nasal COVID-19 Vaccine Moves to First Human Trials

by Okapit | Jan 21, 2025 | Latest news

Rokote Laboratories Finland Oy is starting the first clinical drug trial with its nasal COVID-19 vaccine. The vaccine has been developed and manufactured in Finland, and the study will be conducted at Kuopio University Hospital starting January 21, 2025. The...

Rokote Laboratories Finland Oy Submits First Clinical Trial Application

by Okapit | Jul 18, 2024 | News

The development of the nasal COVID-19 vaccine by the Finnish vaccine development company Rokote Laboratories Finland Oy has successfully progressed to the stage where the company has submitted an application for its first clinical trial. Rokote Laboratories Finland Oy...